The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: Preclinical investigations and results of a phase I dose-escalation clinical trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Cyclin-Dependent Kinases
  • Nerve Sheath Neoplasms
  • Sarcoma

abstract

  • The sequential combination of doxorubicin followed by flavopiridol is well tolerated on both schedules. Disease control was observed in well- and dedifferentiated liposarcoma specifically, a disease in which CDK4 is known to be amplified.

publication date

  • May 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3343204

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-11-3203

PubMed ID

  • 22374332

Additional Document Info

start page

  • 2638

end page

  • 47

volume

  • 18

number

  • 9